Stereotactic ablative body radiotherapy (SABR) uses an intense beam of radiation focussed on the tumour to destroy the cancer cells. This study looks at the long-term effectiveness and safety of SABR for early stage kidney cancer.
The study analysed data from 190 patients who were treated with SABR and followed up for an average of 5 years. SABR failure rate at 5 years was 5·5% overall. There were no serious side effects or treatment-related deaths.
SABR is effective and safe in the long term for patients with primary early stage kidney cancer. These data lend further support for kidney SABR as a treatment option for patients unwilling or unfit to have surgery.